TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›MLTX›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

MoonLake Immunotherapeutics (MLTX) financials

Income statement

MoonLake Immunotherapeutics (MLTX) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating income—-$4.57M-$65.1M-$54.1M-$143M-$245M
Net income—-$4.54M-$50.0M-$36.0M-$119M-$227M
EPS (diluted)—-$0.31-$1.70-$0.73-$1.89-$3.53

Cash flow

MoonLake Immunotherapeutics (MLTX) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow—-$611K-$55.9M-$42.8M-$117M-$196M
Capital expenditures——$16.0K$284K$520K$35.0K
Free cash flow——-$55.9M-$43.1M-$117M-$196M
Share buybacks——$0.00$0.00$50.00—

Balance sheet

MoonLake Immunotherapeutics (MLTX) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$1.34M$8.04M$39.5M$451M$180M$335M
Total assets$117M$9.68M$76.8M$527M$478M$424M
Total liabilities$4.15M$21.3M$8.08M$13.0M$24.5M$120M
Long-term debt————$0.00$74.1M
Shareholders' equity-$2.52M-$11.6M$48.9M$496M$447M$304M
Retained earnings-$2.52M-$53.6M-$80.7M-$117M-$236M-$463M
Shares (wtd avg diluted)—360M29.4M49.1M62.9M64.5M

Every figure is extracted from MoonLake Immunotherapeutics’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is MoonLake Immunotherapeutics's free cash flow?
-$196M in FY2025 (operating cash flow -$196M minus $35.0K of capital expenditures), from the SEC cash-flow statement.
Does MLTX pay a dividend?
MoonLake Immunotherapeutics reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full MLTX analysis — verdict, score & filings →Is MLTX a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.